Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT03154697
Recruiting Observational

Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances

NCT03154697 · tracked via the Priya Life Science USA tracker
Sponsor
Vanda Pharmaceuticals
Phase
Observational
Started
2016-01
Last updated
2024-03-20

Condition(s) studied

Sleep Disturbances in Smith-Magenis Syndrome

Investigational drug(s) / intervention(s)

Data collection of sleep disturbances in individuals with SMS

Data collection of sleep disturbances in individuals with SMS: Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey

Study summary

This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.

Eligibility

Sex
ALL
Min age
3 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Parent or legal guardian of individual with Smith-Magenis Syndrome Exclusion Criteria: * Not legal guardian of individual with SMS

Primary outcome measure(s)

  • Number of individuals with Smith- Magenis syndrome — 5 years

Trial sites (1)

FacilityCityRegionStatus
Vanda Pharmaceuticals Washington D.C. District of Columbia Recruiting

More Vanda Pharmaceuticals trials in the USA

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Active, not recruiting
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension Recruiting
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis Recruiting
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03154697 on ClinicalTrials.gov ↗ ← All trials in the USA